Instil Bio, Inc. Operating Income
Instil Bio, Inc. (TIL) reported Operating Income of -$5.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- Instil Bio, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$5.58M.
- Instil Bio, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$7.01M.
- Instil Bio, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$9.56M.
- Instil Bio, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$15.02M.
- Instil Bio, Inc. operating income (loss) for fiscal 2025 was -$78.58M.
- Instil Bio, Inc. operating income (loss) for fiscal 2024 was -$73.54M.
- Instil Bio, Inc. operating income (loss) for fiscal 2023 was -$159.17M.
- Instil Bio, Inc. operating income (loss) for fiscal 2022 was -$226.46M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.58M 10-Q · filed 2026-08-13 | -$12.59M 10-Q · filed 2026-08-13 | -$22.15M derived: sum of 3 quarters · filed 2026-08-13 | -$37.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$7.01M 10-Q · filed 2026-05-15 | -$16.57M derived: sum of 2 quarters · filed 2026-05-15 | -$31.59M derived: sum of 3 quarters · filed 2026-05-15 | -$55.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$9.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$24.58M derived: sum of 2 quarters · filed 2026-03-27 | -$48.02M derived: sum of 3 quarters · filed 2026-08-13 | -$78.58M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$15.02M 10-Q · filed 2025-11-13 | -$38.46M derived: sum of 2 quarters · filed 2026-08-13 | -$69.02M 10-Q · filed 2025-11-13 | -$80.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$23.44M 10-Q · filed 2026-08-13 | -$54.00M 10-Q · filed 2026-08-13 | -$65.82M derived: sum of 3 quarters · filed 2026-08-13 | -$89.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$30.56M 10-Q · filed 2026-05-15 | -$42.38M derived: sum of 2 quarters · filed 2026-05-15 | -$66.01M derived: sum of 3 quarters · filed 2026-05-15 | -$80.15M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$11.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$35.45M derived: sum of 2 quarters · filed 2026-03-27 | -$49.59M derived: sum of 3 quarters · filed 2026-03-27 | -$73.54M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$23.63M 10-Q · filed 2025-11-13 | -$37.77M derived: sum of 2 quarters · filed 2025-11-13 | -$61.72M 10-Q · filed 2025-11-13 | -$74.74M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$14.13M 10-Q · filed 2025-08-13 | -$38.09M 10-Q · filed 2025-08-13 | -$51.11M derived: sum of 3 quarters · filed 2025-08-13 | -$117.83M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$23.95M 10-Q · filed 2025-05-13 | -$36.98M derived: sum of 2 quarters · filed 2025-05-13 | -$103.69M derived: sum of 3 quarters · filed 2025-05-13 | -$124.68M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$13.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$79.74M derived: sum of 2 quarters · filed 2025-03-04 | -$100.72M derived: sum of 3 quarters · filed 2025-03-04 | -$159.17M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$66.72M 10-Q · filed 2024-11-13 | -$87.70M derived: sum of 2 quarters · filed 2024-11-13 | -$146.15M 10-Q · filed 2024-11-13 | -$202.95M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$20.99M 10-Q · filed 2024-08-13 | -$79.43M 10-Q · filed 2024-08-13 | -$136.23M derived: sum of 3 quarters · filed 2024-08-13 | -$192.88M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$58.45M 10-Q · filed 2024-05-10 | -$115.25M derived: sum of 2 quarters · filed 2024-05-10 | -$171.89M derived: sum of 3 quarters · filed 2024-05-10 | -$230.62M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$56.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$113.45M derived: sum of 2 quarters · filed 2024-03-21 | -$172.17M derived: sum of 3 quarters · filed 2024-03-21 | -$226.46M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$56.65M 10-Q · filed 2023-11-13 | -$115.37M derived: sum of 2 quarters · filed 2023-11-13 | -$169.66M 10-Q · filed 2023-11-13 | -$223.41M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$58.72M 10-Q · filed 2023-08-14 | -$113.01M 10-Q · filed 2023-08-14 | -$166.76M derived: sum of 3 quarters · filed 2023-08-14 | -$209.79M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$54.29M 10-Q · filed 2023-05-11 | -$108.04M derived: sum of 2 quarters · filed 2023-05-11 | -$151.06M derived: sum of 3 quarters · filed 2023-05-11 | -$186.44M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$53.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$96.78M derived: sum of 2 quarters · filed 2023-03-31 | -$132.16M derived: sum of 3 quarters · filed 2023-03-31 | -$155.56M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$43.02M 10-Q · filed 2022-11-14 | -$78.41M derived: sum of 2 quarters · filed 2022-11-14 | -$101.81M 10-Q · filed 2022-11-14 | -$119.28M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$35.38M 10-Q · filed 2022-08-12 | -$58.78M 10-Q · filed 2022-08-12 | -$76.26M derived: sum of 3 quarters · filed 2022-08-12 | -$83.97M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$23.40M 10-Q · filed 2022-05-16 | -$40.88M derived: sum of 2 quarters · filed 2022-05-16 | -$48.59M derived: sum of 3 quarters · filed 2022-05-16 | -$53.18M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$17.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$25.19M derived: sum of 2 quarters · filed 2022-03-07 | -$29.78M derived: sum of 3 quarters · filed 2022-03-07 | -$33.64M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$7.71M 10-Q · filed 2021-11-15 | -$12.30M derived: sum of 2 quarters · filed 2021-11-15 | -$16.17M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$4.59M 10-Q · filed 2021-08-12 | -$8.46M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$3.86M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |